Low Dose Naltrexone Therapy

The Promise of Low Dose Naltrexone Therapy
New LDN book by
Elaine Moore and
SammyJo Wilkinson

Ad proceeds support
LDN education

MS Helping Hands
MS Services & Resources in WA

Promising New Therapy for MS & Immune System Disorders

Latest LDN NEWS

Press Release - Mar 11, 2010
New Website Aims to Clear Up Misconceptions About
Breakthrough Drug Low Dose Naltrexone (LDN)

LDNscience has arrived!
This is the long anticipated collaboration of leading scientific researchers investigating
LDN therapies. A MedInsight Research Institute project.

2010 Two studies show LDN benefits. The LDN study from Penn State, and the human trial of LDN at UCSF. Thank you fellow LDNers for funding 50% of the UCSF trial!

The organizers of International LDN Awareness Week have launched LDNAware, gateway to worldwide LDN groups, information and activism.

International LDN Awareness Week October 18th–24th 2010
Read the Press Release
6th Annual LDN Conference Birmingham, UK Oct. 23th, 2010

Dr. Chris Steele, MBE, on Low Dose Naltrexone, LDN

Sept 2009, Dr Chris is the UK equivalent to Dr Oz in USA
He supports supports the UK LDN petition!

(Here is a list of more doctors who support LDN use)

(LDN Youtube video)

(More LDN News below...)

The Promise Of Low Dose Naltrexone Therapy:
Potential Benefits in Cancer, Autoimmune, Neurological
and Infectious Disorders

By Elaine Moore, co-author SammyJo Wilkinson
Foreword by Dr. Yash Agrawal, MD, PhD

Published by McFarland Publishing
Available at Amazon / Barnes & Noble
Book Description & Order Sheet

Commentaries: Ronald Hoffman, MD | Jeffrey Dach. MD | Yash Agrawal, MD, PhD

Book Review by Maija Haavisto

The off-label protocol referred to as Low Dose Naltrexone (LDN) modulates the immune system and promotes healing. Relying on clinical trial results and interviews with the leading LDN researchers worldwide, we describe the history of LDN and explain its biochemical and molecular effects. In clinical trials, LDN has been shown to halt disease progression in Crohn’s disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis (MS) and autism. Ongoing trials are evaluating LDN in fibromyalgia and HIV/AIDS. Anecdotally, LDN has been shown to improve almost every autoimmune and neurodegenerative condition, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Chapter One	The War on Drugs, A History of Naltrexone
Chapter Two	LDN in Autoimmune Diseases
Chapter Three	LDN in Multiple Sclerosis
Chapter Four	LDN in Neurodegenerative Disorders
Chapter Five	LDN in Cancer
Chapter Six	LDN in Autism Spectrum Disorders
Chapter Seven	LDN in Wound Healing and Infections
Chapter Eight	The Immune System and LDN in HIV/AIDS
Chapter Nine	The LDN Experience: A Patient’s Guide to LDN
Chapter Ten	The Potential Benefits and Future of LDN
Chapter Eleven	Resources
Appendix A	LDN Clinical Trials
Appendix B	LDN Survey
Appendix C	LDN Survey Analysis

A BIG thank you to Elaine Moore for making this book a reality. She is an extensively published medical author. This book will be an invaluable reference for researchers, practitioners and patients who want to understand the therapeutic potential of LDN.

Sign SammyJo's guestbook to be notified of LDN research updates.

Visitors

278,541

My name is SammyJo, I'm an MS patient who has experienced remarkable recovery from MS misery. Research is proving that using a low dose of the FDA approved drug Naltrexone is helpful in treating many immune system disorders. LDNers.org is dedicated to helping patients get better with LDN.

Join SammyJo on Facebook

Sign the World LDN Petition
Over 11,400 so far!

Post Your LDN Results
Patient Tracking Database

Meet the LDN Advocates! Vicki Finlayson walked 53 miles for LDN research!

5th Annual LDN Conference
NIH Headquarters
Oct. 19th 2009 Bethesda, MD

4th Annual LDN Conference and interview videos.
Oct. 11th 2008 in LA

Latest LDN NEWS

Radio interviews with Elaine Moore & SammyJo Wilkinson, authors of the The Promise Of Low Dose Naltrexone Therapy. Follow these links to listen live on the Web or to the show archive.

Health Talk with Dr. Ronald Hoffman-September 23,2009 -Listen Now Sept. 2009 Interview with Elaine A. Moore.

Mary Boyle Bradley Talk Radio -Listen Now

Wide World of Health Host Cary Nosler - AM Talk 650 KSTE Sacramento.
< Click this arrow to listen now or download podcast.

Wellness TalkRadio Host Kris Costello - AM 1440 Santa Barbara.
July 22th Wednesday

UK woman petitions government for LDN trials. Visit ldnnow.co.uk
July 6 2009, Western Telegraph

Could This Powerful Breakthrough Beat Cancer and Auto-Immune Diseases?
Mercola Interviews Dr. Berkson on Low Dose Naltrexone

Interview: Burt Berkson, MD, PhD, Talks With Julia Schopick about Alpha Lipoic Acid and LDN, at HonestMedicine.com

Stanford pilot results: Low-Dose Naltrexone Reduces the Symptoms of Fibromyalgia - April 2009
Interview with Stanford researchers TV News Report WWLTV

Low Dose Naltrexone trial at Stanford for Gulf War Syndrome
Article by Elaine Moore

Glasgow GP Brings First LDN Conference To Europe To Help Raise Awareness Of Treatment For Autoimmune Diseases
Held in Glasgow Saturday, April 25

More Than a Magic Bullet: Low Dose Naltrexone
Article by Elaine Moore for EMaxHealth

Interview: Burt Berkson, MD, PhD, Talks With Honest Medicine About
His Work With Alpha Lipoic Acid and Low Dose Naltrexone (audio & text)
Interviewed by Julia Schopick Mar '09 for HonestMedicine.com

New! LDN Patient Tracking Database for all diseases. Post your results!
   MS survey matches SammyJo's 2004 survey for comparison.
   This is no longer "just anecdotes" - this is Patient Based Evidence!
   Read Julia Schopick's "Anecdotal" Series: Six Articles

A Case of Remission from Crohn's Disease. Reported by Jeffrey Dach MD

LDN commentary by Yash Agrawal, MD
Dec 20, Dr. Agrawal adds some further thoughts to the his hypothesis on LDN for MS, published in 2005. And comments on the new LDN book, for which he wrote the foreward.

Low-dose naltrexone for disease prevention and quality of life
Nov 26, Brown N, Panksepp J., Medical Hypotheses. Overview of current trials and theories on how LDN benefits a wide variety of illnesses. Abstract.

Four LDN Studies Presented at the 2008 MS World Congress Meeting
Sept 22nd, Elaine Moore reports on the important MS/LDN studies at Penn State and University of California.

Low Dose Naltrexone: Hope for PPMS
Sept 18th, Maija Haavisto reports on the Italian human trial 6 month report.
This is the first LDN-MS trial data published - Abstract J. Mult. Scler. Sept 08

Daily Mail reports another positive LDN story
Aug 25th The Daily Mail, London

Wonder Drug: LDN has potential to help tens-of-thousands of patients with diseases like Crohn's, multiple sclerosis, Lupus, parkinson's and even HIV. (News interviews with Dr. Ian Zagon and Dr. Jill Smith, LDN researchers at Penn State) Print version to show your doctor.
May 21th By Ali Gorman, RN -ABC News affiliate in Hershey Pennsylvania

and many more reports in the Media section...

GO VICKI !!!

Oct. 21st 2009: Vicki will be back on the Sacramento Capitol steps.

A promising MS drug has her walkin' - Vicki Finlayson says LDN has her walking strongly again

May 16 2008 Sacramento Bee, Front Page

Capitol Stride: Lake of the Pines woman walking 53 miles to promote MS drug - Additional pictures of Vicki Finlayson's LDN walk

May 16 Auburn Journal, Front Page

More details on Vicki's LDN Awareness Walk...

Four Lifesaving Medical Treatments: Not So "Anecdotal," After All!
May 2008 By Julia Schopick, HonestMedicine.com
Review of little known but effective medical protocols, including LDN.

Low Dose Naltrexone Update-The Benefits of LDN in Autoimmune Disease

Article by Elaine Moore

Stanford's Clinical Trial of Naltrexone for Fibromyalgia Recruiting Patients
Story by Elaine Moore

LDN in the Treatment of HIV in Mali, Africa

The Use of LDN for MS, Crohn's, and Other Autoimmune Diseases
Article by Elaine Moore

WE DID IT !!!
The LDN for MS Research Fund raised $25,000 in 2006
It has been given to the Univ. CA San Francisco MS Research Center.
A crossover study to evaluated the effect of LDN on MS has been completed on 80 patients with MS, to be published Spring '08. Show your Dr this study!

Press Release: Patient Advocates With Multiple Sclerosis Fund Clinical Trial of Promising Drug Many Say Has Helped; University of California, San Francisco MS Center to Conduct Study of Low-Dose Naltrexone

Thank you to individual contributors and those who put on fundraising events!

Speakers:
SammyJo, Vicki, Mary Anne Boyle-Bradley
Bill Wills, Pharmacist

"An Evening at Lake of the Pines"

To Benefit the LDN research Fund and
Accelerated Cure Project for Multiple Sclerosis
hosted by Vicki Finlayson

September 17, 2006 4 p.m. Lake of the Pines Country Club Auburn, CA

LDN Fundraiser: Former firefighter Bill Roberts turned his life around in the past year with LDN. He has rallied his firefighter friends in the effort to get trials started to have the drug approved for treatment of Multiple Sclerosis. Read more...

LDN Fundraiser: Sierra Doherty is hiking the Colorado Trail to raise money for LDN research! Her mom has MS and uses LDN. Click here to donate to her effort
-and get updates on Sierra's quest !

There are exciting developments in Low Dose Naltrexone (LDN) research. Visit the Research section for details on:

Publication of the first medical hypothesis on LDN therapy for MS

Status of clinical trials for LDN

Annual LDN Conferences

First Annual LDN Conference June 11th 2005 in NYC
SammyJo's Presentation (PDF) | Conference Snapshots
Post conference summary | Dr Larry Frieders summary |Attendee commentary

Patient Initiated Research / Evidence-based Medicine

Four key questions answered by 267 LDN users in Survey 1:

Very low relapse rate of 0.2, or 1 in 5 years
70% report symptom improvement
45% think progression has stopped
76% say LDN is working for them, & will continue therapy

I started this site in the Spring of 2004 to confirm that others were seeing the same positive results I was. Thank you to the hundreds of LDNers contributing their experiences. I hope scientific research will accelerate and determine why so many of us are experiencing positive results.

Change in EDSS disability score before & after LDN is measured by Survey 2.

Follow the Surveys link for result details.

The surveys are comprised of a representative sampling of all types of MS (RRMS, SPMS, PPMS). This is important information from patients on the frontlines, and must be followed up by clinical researchers.

Naltrexone is an FDA-approved drug. LDN is an off-label use of naltrexone in a low dosage. It does requires a prescription from a doctor. See Resources for help finding a prescriber or pharmacy, and info on LDN for other autoimmune disorders, cancer or HIV.

"Never doubt that a small group of thoughtful committed citizens can change the world; indeed, it’s the only thing that ever has."
- Margaret Mead

HealingPowerNow.com